, Tracking Stock Market Picks
Enter Symbol:
Rating: VRA

Vera Bradley, Inc. (NASDAQ: VRA) reiterated to Buy by Standpoint Research

Friday,  Jan 15, 2016  1:25 PM ET by Lynn Gilbert

Standpoint Research reiterated Vera Bradley, Inc. (NASDAQ: VRA) to Buy. Previously, Standpoint
Research rated Vera Bradley, Inc. (NASDAQ: VRA) to Buy with price target $18 on 12/09/2015, when the stock price was valued at $15.75.

Vera Bradley, Inc. (Vera Bradley) is a designer, producer, marketer, and retailer of accessories for women. The Company?s products include offering of handbags, accessories, and travel and leisure items. Vera Bradley operates in two segments: Indirect and Direct. As of January 29, 2011, its indirect business consisted of sales of Vera Bradley products to approximately 3,300 independent retailers, substantially all of which are located in the United States, as well as select national retailers and third party e-commerce sites. As of January 29, 2011, its direct business consisted of sales of its products through its 35 full-price stores, its four outlet stores,, and its annual outlet sale in Fort Wayne, Indiana. Its handbag product category includes totes and specialty bags, such as baby bags, backpacks, and laptop portfolios. Its accessories include fashion accessories, such as wallets, identity cases, eyeglass cases, cosmetics, paper and gift products, and eyewear.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy